Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
3
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
4 competitors in Plaque Psoriasis
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Daliresp
Daliresp is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.
View on EMALibertek
Libertek is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.
View on EMADaxas
Daxas is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.
View on EMA